NCT07302945已完成1 期
High-Resolution Immune Dynamics Following OTS-412 Oncolytic Vaccinia Virus Administration in a Healthy Volunteer(Self-experiment)
Bionoxx Inc.1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2022年1月4日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Changes in ANC(absolute neutrophil count) over time
研究概览
简要总结
Following oncolytic virus (OV) administration, the host immune response is initiated immediately and evolves dynamically. However, in clinical OV therapy, it is virtually impossible to capture these immune events in real time. To address this gap, the principal investigator conducted a high-resolution immune monitoring study in a healthy volunteer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •A healthy adult
排除标准
- 未提供
研究组 & 干预措施
OV Treated healthy arm
Experimental
干预措施: OTS-412 (Biological)
结局指标
主要结局
Changes in ANC(absolute neutrophil count) over time
时间窗: 4 hour, 8 hour, 20 hour, 24 hour, Day 2, Day 5, Day 8, Day 16
Changes in lymphocytes count over time
时间窗: 4 hour, 8 hour, 20 hour, 24 hour, Day 2, Day 5, Day 8, Day 16
次要结局
- FLow cytometry(4 hour, 8 hour, 20 hour, 24 hour, Day 2, Day 5, Day 8, Day 16)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid TumorsNCT07262164Shanghai Virogin Biotech Co., Ltd.30
招募中
1 期
Oncolytic virus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in the treatment of melanomaMelanoma2024-514092-18-00TILT Biotherapeutics Oy9
招募中
不适用
Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021NCT07302607University Hospital, Strasbourg, France221
招募中
2 期
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in InfantsNCT07286370GlaxoSmithKline537
招募中
2 期
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia2023-504694-20-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)131
